Remedy Pharmaceuticals Inc., of New York, said it completed a $9 million financing led by Vertical GP-5 LLC, an affiliate of The Vertical Group, and other new investors with participation from existing investors. The funds will be used to accelerate the company's pathway to a phase III study of its lead compound, Cirara, a high-affinity inhibitor of Sur1-Trpm4 channels, in severe stroke.